The following publications have used samples or data from the Basel Liver Biobank. Researchers using our resources are requested to acknowledge the Basel Liver Biobank in their publications.

2025

• Sequera C, et al. The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active. Nat Commun 2025;16:7919. DOI
• Muller M, et al. Human-correlated genetic models identify precision therapy for liver cancer. Nature 2025;639:754–764. DOI
• Kaldjob-Heinrich L, et al. Adenosine Receptor 3 in Liver Cancer. Gastro Hep Adv 2025;4:100590. DOI
• Chancellor A, et al. The carbonyl nucleobase adduct M(3)Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells. Immunity 2025;58:431–447. DOI

2024

• Zhang X, et al. Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib. EBioMedicine 2024;109:105368. DOI
• Blukacz L, et al. Inhibition of ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC. Hepatol Commun 2024;8. DOI

2023

• Schaeffer S, et al. Ribociclib-induced liver injury: a case report. Front Oncol 2023;13:1256783. DOI
• Pu W, et al. Bipotent transitional liver progenitor cells contribute to liver regeneration. Nat Genet 2023;55:651–664. DOI
• Nikolaou KC, et al. Inflammation-induced TRIM21 represses hepatic steatosis. JCI Insight 2023;8. DOI
• Mossmann D, et al. Arginine reprograms metabolism in liver cancer via RBM39. Cell 2023;186:5068–5083. DOI

2022

• Suter P, et al. Multi-omics subtyping of hepatocellular carcinoma patients using a Bayesian network mixture model. PLoS Comput Biol 2022;18:e1009767. DOI
• Suslov A, et al. Studying Hepatitis Virus-Host Interactions in Patient Liver Biopsies. Viruses 2022;14. DOI
• Park S, et al. Transcription factors TEAD2 and E2A globally repress acetyl-CoA synthesis to promote tumorigenesis. Mol Cell 2022;82:4246–4261. DOI
• Ng CKY, et al. Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages. Nat Commun 2022;13:2436. DOI
• Meier MA, et al. Patient-derived tumor organoids for personalized medicine in rare hepatocellular carcinoma. Commun Med 2022;2:80. DOI
• Lett MJ, et al. Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised by human liver cells. Gut 2022;71:2526–2538. DOI
• Gallon J, et al. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol 2022;16:665–682. DOI

2021

• Suslov A, et al. Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. J Hepatol 2021;74:794–800. DOI
• Nuciforo S & Heim MH. Organoids to model liver disease. JHEP Rep 2021;3:100198. DOI
• Meier MA, et al. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol 2021;75:840–847. DOI
• Gao R, et al. USP29-mediated HIF1alpha stabilization is associated with Sorafenib resistance of HCC cells. Oncogenesis 2021;10:52. DOI
• Ding L, et al. Peroxisomal beta-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis. Nat Metab 2021;3:1648–1661. DOI
• Coto-Llerena M, et al. Interferon lambda 4 can directly activate human CD19(+) B cells and CD8(+) T cells. Life Sci Alliance 2021;4. DOI
• Chen Q, et al. Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses. Nat Commun 2021;12:4882. DOI
• Boldanova T, et al. Supervised learning based on tumor imaging and biopsy transcriptomics predicts response of HCC to TACE. Cell Rep Med 2021;2:100444. DOI

2020

• Tran HTL, et al. OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. PLoS One 2020;15:e0236447. DOI
• Kinast V, et al. C19orf66 is an interferon-induced inhibitor of HCV replication. J Hepatol 2020;73:549–558. DOI
• Di Blasi D, et al. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol 2020;9:195–218. DOI
• Brenig R, et al. Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis. Life Sci Alliance 2020;3. DOI

2019

• Tang F, et al. LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function. Nat Commun 2019;10:5755. DOI
• Flecken T, et al. Mapping the Heterogeneity of Histone Modifications on Hepatitis B Virus DNA. J Virol 2019;93. DOI
• Calabrese D, et al. Liver biopsy derived induced pluripotent stem cells provide unlimited supply for hepatocyte-like cells. PLoS One 2019;14:e0221762. DOI
• Blumer T, et al. Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve Originating Tumor Characteristics. Hepatol Commun 2019;3:971–986. DOI

2018

• Suslov A, et al. Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver. Gastroenterology 2018;154:1778–1790. DOI
• Nuciforo S, et al. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Rep 2018;24:1363–1376. DOI
• Ng CKY, et al. Genetic profiling using plasma-derived cell-free DNA in therapy-naive HCC patients. Ann Oncol 2018;29:1286–1291. DOI
• Hindupur SK, et al. The protein histidine phosphatase LHPP is a tumour suppressor. Nature 2018;555:678–682. DOI
• Campana B, et al. In vivo analysis of steatosis induction in HCV genotype 1 and 3 infections. J Viral Hepat 2018;25:262–271. DOI

2017

• Rey S, et al. Liver damage and senescence increases in patients developing hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:1480–1486. DOI
• Meier MA, et al. Hepatitis B virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway. J Viral Hepat 2017;24:662–671. DOI
• Guri Y, et al. mTORC2 Promotes Tumorigenesis via Lipid Synthesis. Cancer Cell 2017;32:807–823. DOI
• Boldanova T, et al. Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liver. EMBO Mol Med 2017;9:816–834. DOI
• Blumer T, et al. SOCS1 is an inducible negative regulator of interferon lambda-induced gene expression in vivo. J Biol Chem 2017;292:17928–17938. DOI

2016

• Planas-Paz L, et al. The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size. Nat Cell Biol 2016;18:467–479. DOI
• Makowska Z, et al. Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-based molecular classifications of HCC. J Pathol Clin Res 2016;2:80–92. DOI
• Dazert E, et al. Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. PNAS 2016;113:1381–1386. DOI

2015

• Marti P, et al. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology 2015;62:1497–1510. DOI
• Mailly L, et al. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 2015;33:549–554. DOI
• Anggakusuma, et al. Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication. Hepatology 2015;62:702–714. DOI

2014

• Wieland S, et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 2014;59:2121–2130. DOI
• Terczynska-Dyla E, et al. Reduced IFNlambda4 activity is associated with improved HCV clearance. Nat Commun 2014;5:5699. DOI
• Quagliata L, et al. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression in HCC. Hepatology 2014;59:911–923. DOI
• Lucifora J, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221–1228. DOI
• Lange CM, et al. Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to IFN-alpha. J Immunol 2014;192:6037–6044. DOI